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obipctiws. This study was done to determine the incidence, 
timing and prevaieoce as a cause of death from cardiac roptore in 
patients with acote myocardial Muctioo. 
i?dgrmd Several dinid trials sod overview analyses have 
s-ted that t4e swvival bet&t conferred by tIuombolytic 
t~.lpymsykollsetbya~~eisereaseinearfydeatbsfrom 
cardiac niptore. 
MM. Demogmphie, pmcedorat and ootwme data Polo 
patients with acute myocardiai hfordion vwe co&ted at 1,073 
united states 4o5pitals CollablJratiBg in t4e united states Na- 
tionai Registry of R4yoeaNliol khretioo. 
ltesuk Among the 354755 patients enrow 12293 received 
tbnmbol* ulerapy. In-hospital moxtolity for the overall potieot 
populatioo, those not treated with tbrombolyucS (n = 22&m) 
and those giveo thromm were IO&J, 12.9% ood S.!%, 
respectively (p c O.tw). rJuvhgenic shock was the most commoo 
came of death in each patient groop. Altboogb tk iocideoee of 
cardiac rupture was low (CI.O%), it was rqmosibte for 7.3%, 
6.1% sod 12.1%, respectively, of io-hospital de&s (p < 0401). 
Deatbfrumqtnreocxomxtearliiinpotieots@veothmbo- 
lytic therapy, with a dostering of events witbin 24 II of drq 
odministra~ Despite the early ri* de& rates were compor- 
atively low io thromboiytii-trested patieots oo ead~ of the tkst 38 
days. By moltivariabk anolysi~ tkosW+q prior m 
iofardiop,advanc@gpp,femole~rondWwenoesbeta- 
blocker use - iodependeotiy associated with cardii nrpton~. 
conchLdonr.T4iilprperegist3ye~ i~ovee 
3xl,wJ@ patients with lnpealdial ithmtkq sllggsts that tksom- 
bdytiitktempyaueleratescardiae~~towitliin24 
to48hoftmbnent.TbepossibiJitytlmtmptnrempwntsap 
eariybemonBsgienwpultioaoft~tberapys4on~be 
investigated. 
(J Am Cofl GmiW 199@27:1321-6) 
Clinical observations made in several large-scale randomized 
trials (I-3) coupled with those from a recently published 
collaborative overview (4) suggest that thrombolytic therapy 
when used in the treatment of myocardial infarction, although 
clearly reducing overall patient mortality, may be associated 
with an increased number of deaths during the initial 24 to 
48 h. The mechanisms responsible for this early iisk have not 
been &fined fully: however, there is some suggestiin that 
cardiac rupture may be responstble. In GISSI-1 (lJ), the 
increased number of deaths during the first 6 h among patients 
given intravenous streptokinase was largely attributed to elec- 
tromechanical dissociation (potentially a manifestation of car- 
diac rupture and pe&rrdial tamponade) and heart failure. An 
excess of cardiac rupture events within the fii% 48 h was reported 
in the International Study of Infarct Survival (ISIS-2) (2). 
To characterixe the causes of death among patients with 
myocardial infarction given thrombolytic therapy and to ex- 
plore the possible relationship between early death and cardiac 
rupture. mortality data from the United States National Reg- 
istry of Myocardtal Infarction were analyxed. 
Methods 
The United States National Registry of Myocardial Infarc- 
tion (NRMI) was initiated in 1989 as a pilot projed for patients 
with chest pain. A large-scale registty ~eventually inchiding a 
total of 1,073 hospitals was fitst establiihed in 1990 for the 
putpose of collecting uniform data on the treatment of acute 
my-iBfaraioothatanddbeusedtoanahlpenetiooal 
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Table 1. National Reaistrv of Xvocardial Infarction: Total Patient Population All-Cause Mortalitv 
AU MI Patients 
No lluomMytic Thmmbdytic 
llterapy Therapy p Value’ 
Number of patieats (tt) 350,755 228,512 91318 
Cause of death (%, n) 
cardiogenie shock 35% (12,262) 4.1% (9,437) 2.3% (2,054) < O.OlIl 
sudden eardii arrest 2.9% (10217) 3.7% (8,435) t.5%(1,282) < O.cQl 
E% 
1.5% (5,385) 1.9% (4,279) O.% (794) < 0.001 
0.7% (2,511) zxz ;:,993) 0.4% (384) < 0.001 
Eh4DhUpiW~ 0.8% (2,671) 0.8% (1.801) 0.7% (631) < 0.001 
Ott1 cardiac 1.2% (4,221) 1.6% (3,556) 0.5% (468) < 0.001 
clvmu motlaiily 10.4% (36,581) 12.9% (29,401) ‘.9% (5,165) < Osml 
*Pearson chiquate test, patients with versus those without thrombolytic therapy. EMD = electromechanical 
discbtion: Ml = mywardii infarction. 
practice patterns and to facilitate continuous quality improve- 
ment for individual participating hospitals (6). 
Demographic, procedural and outcome data on patients 
with acnte myocardiai infarction were collected by an ap- 
pointed coordinator at each site. To be inch&d in the 
Registry, patients were required to have experienced an acute 
myocadial &r&on documented by local hospital criteria, 
typica& with cardii enzymes (crcatine base and its MB 
fraction), ekxWxx&mphy or coronary angiography. 
All data were sent to a central data c&&ion center (Clin 
Trials Research, Inc., Lexington, KY) for processing and 
analysis. Double-key entry was used to add each case report 
formtothedatabase. 
StatisticaI analysis. The frequency of rupture events was 
analyzed using the chi-square test statistic. Comparisons were 
then made between the thrombolytic and nonthrombolytic 
patient groups. The time to death data were analyzed using 
smvival adysis methods. The life test procedure (SAS 6.06) 
was used to compute estimates of the survival function. A 
separate ~~TGwI curve was e&mated for tbe thrombolytic and 
nonthrombo@ic patient group, and the log rank test was 
cslculated to determine whether the two samplea could be 
modeled by the same survival function. 
A logistic regression analysis was used to test the relation- 
ship between the binary response variable (cardiac rupture) 
and explanatory variabk or covariates (age, sex, medications, 
myocardial &rction location, time to treatment and throm- 
boiytic dosing strategy). For multivariabIe analyses, the signif- 
icance of each regression variable was adjusted for other 
vatiablca used in the model. 
Results 
The 1,073 participating hospitals comprise nearly 15% of all 
United States hospitals In general, they are larger, more likely 
tohaveacuteca&ccareand&xventionalcapab&&and 
mcKefrequenuyaffiliatedwithmedicaischookthannomgis- 
trybospitais.TheNRMIdatabasecurrentlyindudeaover 
350,000 ptienta with nyocardial infanS@ and the present 
~d~~~~~~~~~~t~~~ 
of De& 1994. 
Data from a total cohort of 350,755 patients with myocar- 
dial infarction were available for analysis. More than two- 
thirds of all patients did not receive thrombolytics. Among 
those treated with thrombolytics, tissue-type plasminogen ac- 
tivator (t-PA) was the most commordy used agent (75%). 
In-hospital al&cause cardiac mortality for the overall pa- 
tient population (n = 350,755), those not treated with throm- 
bolytics (n = 228,512) and those administered thrombolytica 
(n y 122,243) was 10.4%, 12.9% and 5.9%, respectively 
(p < 0.001) (Table 1). The most common cause of death within 
each group was cardiogenic shock, occurring in 3.5%, 4.1% 
and 2.3% of patients, respectively (p < 0.001). Overall, cardiac 
rupture/electromechanical dissociation (EMD) occurred in 
fewer than 1.0% of patients experiencing myocardial infarc- 
tion; however, among patients with in-hospital mortality, car- 
diac rupture was responsible for a greater proportion of deaths 
in thrombolytic-treated patients (Tables 1 and 2). By multiva- 
riable logistic regression, thrombolytics, prior infarction, ad- 
vancing age, female sex and intravenous beta-blocker use were 
independently associated with cardiac rupture (all p < 0.001). 
Demographic variables, baseline characteristics and treat- 
ment parameters for patients treated with tbrombolytin who 
experienced in-hospital death are shown in Table 3. There 
were no sign&ant differences in age or gender for patients 
dying from cardiac rupture/EMD compared to those dying 
from other cardiac causes. For those treated with t-PA, neither 
the total dose, dosing strategy nor site of infarction appeared 
to dii intluence the OFcumence of cardiac rupture/EMD. 
Although a majority of patients dying from cardiac rupture had 
received intravenous hem its use was also common in those 
dying from other cardiac causes. Aspirin use was more com- 
mon among patients with, as compared to patients without, 
cardiac ~pturc/EMD (71.7% versus 66.70/o, p = 0.003). Intra- 
venous beta-blocker use. did not differ signiiicantly between 
groups (p = 0.18). 
Gmsideriug the overall patient population with in-hospital 
mortality (Table 4), the time fmm hospital presentation to 
death (ail cause) and death from cardiac ruph@EMD aver- 
aged 6.3 and 3.4 days, respectively (p C 0.001). Patients with 
~~~~ern~~toh~e~~~~ 
~o~~~~r~(~e~or~)~~ 
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Table 2 National Registry of Myocardiat Iafarction: Patient Population With In-Hospital Mortality 
NoThrombdyk ‘Ibrombdytic 
A0 MI Patients *WY p Vaw 
Number of patients (n) MS81 R408 1,173 
Came of death (%, n) 
Cardiqcnic shock 335% (12,262) 32.1% (9,437) 39.4% (2,054) < 0.l.m 
snddencardiiarNa 27.9% (10,251j 28.7% (8,435) 24.8% (1,282) < o.uu 
- 14.7% (5J85) 14.6% (4,279) 15.4% (794, 0.068 
ReFunent IMI 6.9% (2,511) 6.8% (1,993) 7.2% (384) 0.153 
EMDhpw 73% (2,671) 6.1% (l,&ll) 121% (631) < 0.001 
othercardhc 115% (4,221) 12.1% (3556) 9.3% (468) c 0.001 
*Pearson cbi-square test, fwients with velsas the without thmmbolytic tbeapy. EMD = elearomechartical 
dissociation; Ml = mywardial i&r&a, 
aspirin (aII p < 0.001) than patients without this compkatiox 
Among patients treated with tttrombolytics, the representative 
times were 4.9 and 2.7 days, respectively @ < 0.001). Patients 
receiving thromboIytic therapy died eadier than those not 
given a tIuomboIytic agent (4.9 vs. 6.3 days, p < 0.001). Earlier 
death was most notable in patients experiencing cardiac raptt& 
EMD, in whom thromboIytic-treated and nor&omMytic 
patients died on average, 2 or 3 days earIier than those dying of 
other cardiac causes. Earlier death was particuIarIy azmmon in 
tIuomboIytic-treated patients experiencing car&c rupture/ 
EMD. In these patients, death occurred nearly 4 days eartier 
than in patients not given a thromboIytic who died of other 
causes (2.7 vs. 6.3 days, p < O.OOl), 1 day earIier than 
nonthromboIytic patients with cardiac rapture/EML) (2.3 vs. 
3.7 days, p < O.oOl), and more than 2 days earlier than 
tbromMytic-treated patients dying of other causes (2.7 versus 
4.9 days, p < 0.001). There was a definite clustering of cardiac 
ruptare deaths during the Iirst 24 II atier treatment initiation 
when thromboIytics were admkkred 
Hazard fmction amIyses for the ov&I patient popidation 
experiencing ia-hqitaI death (aII cause) (Fii. 1) and for &use 
dying from cardiac rupture (Fig. 2) and noncardiac rupture/ 
EMD(Fii3)areprese.nted.Dtuiageachofthefirst3Oda~ 
deathwasmore common among patients not receiving throm- 
hoIytic therapy. In both groups (thromholytic- and non- 
thromboIytic-treated), mortality was highest during the initiaI 
48 to 72 h. klthough ruptarelEMD deaths were more preva- 
Ient in thromboIytic patients on day 1, these patients (consid- 
Table 3. National Registry of Myocardiai hfarcth Tbromhlytic-Treated Path& With 
In-Hospital Mortality 
EMIJerdial Rupture 
YCS No p VatlIe’ 
Number of Patients (n) 
Age, mcan -t mu (II) 
Gender (n) 
m. 9% ho 
InIarcdon site (II) 
Anterior, % (n) 
lnkrior, % (0) 
Posterior, % (0) 
T&al t-PA dose, mean 2 SEM (n) 
Type of t-PA dosing (n) 
Fromloaded. 96 (n) 
Weight-acljusteQ I (n) 
Stamlard 96 (n) 
coormaitsnt medicatioN (a) 
lV hepa@ 96 (n) 
lV betabla$er 96 (n) 
Aspirio. % (0) 
Tiifmmoasetofcbtpsinto 
treatamt,mcan~SEbf(n) 
Tiifmmtremaeattodealh, 
870 
70.6 + 0.3 yT (tuil) 
866 
!a.% (437) 
631 
53.7% (339) 
41.0% (259) 
7.6% (48) 
95.1 It 0.7 mg (SW) 
631 
50.4% (318) 
s-9% (W 
34.9% (zzo) 
87u 
921% (375) 
17.1% (149) 
71.7% (624) 
4.7 ? 02 b (501) 
WQ 
xl.4 I 0.1 yr (6,244) 
5$3!453) 
4534 
WE4 Gwv 
42.3% (1,916) 
7.2% (328) 
9s 2 03 (4.3251 mg 
4334 
51.2% c39 
lO.tr% (454) 
363% (1.648) 
633 
915% (5.770) 
15.4% (%9) 
66.8% (4203) 
4.8 + 0.1 b (3,533) 
5.1 z 0.1 day (4,332) 
0.754 
0.007 
0324 
0.910 
0.426 
0590 
a%2 
0.493 
a505 
0.016 
0.182 
0.003 
0.43a 
< O.twl 
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Table 4. National Registry of Myocardial Infarction: Timing of In-Hospital Death 
No Thrombol>2ic 
Therapy 
6.3 ?: 0. I days (2X&X) 
Thmmbo@ic 
Tbmpy 
4.9 + 0.1 days (6,954) 
p Value’ 
< 0.001 
Hospital All MI Patients 
Tii from presentatioa to death, mean + SEM (n) 6.1 + 0.0 days (35,442) 
RupkwEMD: yes, mean +_ SEM (a) 
Rapture/EMD: no, mean 5 SEM (a) 
3.4 2 0.1 day5 (2,621) 3.7?0.1days(1,762) 2.7 2 0. I dalyF (X59) < 0.001 
6.3 2 0.0 days (32,821) 6.5 .’ 0.1 days (26,726) 5.2 t 0.1 d?ys (6,095) < 0.001 
p&et <0.001 < Q.nol <OWl 
‘Patients with versus thme without thrombolytic therapy. tPatients with vetsus those without myocardial Nptureielectromechanical dissociation (EMD). The 
Wilcoxoa tes was used to compare lime intervals. MI = myocardial inlarcrion. 
ered as a group) were still less likely to die than those in whom 
thrombolytic therapy was not administered. 
evidence that it reduces both in-hospital (10-13) and long- 
Discussion 
The NRMI provides a unique resource for assessing clinical 
outcomes and health care trends among patients with acute 
myocardial infarction. In our evaluation of over 350,000 pa- 
tients, several observations were made. First, the overall 
incidence of cardiac rupture, although not substantially in- 
creased with thrombolytic administration, was responsible for 
a larger proportion of in-hospital fatal events, particularly early 
deaths. Second, in contrast to the prethrombolytic era (7-9), 
most cardiac ruptures associated with thrombolytic therapy 
occurred within 24 to 48 h of infarction rather than later (days 
3 to 5) in the hospital course. Last, despite the higher 
frequency of cardiac rupture as a cause of death, thrombolytic 
therapy was associated with a comparativeIy low in-hospital 
mortaIity. Thus, the information provided by the largest exist- 
ing voluntary data base suggests that cardiac rupture is accel- 
erated by tbrombolytic therapy and is responsible for a greater 
proporfion of early deaths. 
Thromb@tIe therapy and sarIy risk. Thrombolytic ther- 
apy has emerged as the standard of care in the treatment of 
patients with acute myocardial infarction. There is unequivocal 
Figure 1. Hazard function for death (ail cause) during the initial 30 
days atier myocardial infarction (all patients). Death was more com- 
mon on each successive day among patients not given thrombolytic 
therapy. 
w- 
term (9,10,14,15) mortality. However, concerns have been 
raised that there may be an “early hazard” associated with 
thrombolytic treatment. Several studies have shown a lack of 
mortality difference within the first 24 h when comparing 
patients treated with thrombolytics and those given standard 
care (1,2). This observation was first made in GISSI-1 (1,s). 
where, despite a 20% reduction in overall mortality, tbzre were 
approximately 50 more deaths among streptokinase-treated 
patients during the initial 24 h. The excess mortality was 
concentrated in the first 6 h and attributed largely to electro- 
mechanical dissociation and heart failure. 
The causes of death among patients dying within 18 h of 
enrollment in the Thrombolysis in Myocardial Infarction Phase 
II (TIM1 II) study have been outlined by KIeiman and col- 
leagues (16). Of 3,339 patients enrolled, 32 died within the first 
4 h following treatment initiation, and 31 died within the 
subsequent 14 h. To estimate the rates at which deaths 
occurred, a piecewise exponential survival model was em- 
ployed, showing a greater proportion of deaths within the first 
18 h (particularly the first 4 h). Similar to observations derived 
from the NRMI, pump failure was the most frequent cause of 
death, but cardiac rupture was responsible for approximately 
Fire 2. Hazard function for death from cardiac rupturelelectro- 
mechanical dissociation in patients treated and those not treated with 
thrombolytics. Rupture was more common during the initial 48 b in 
thrombolytic-treated patients. 
kkzad 
m 
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Figure 3. Hazard function for deaths (excluding cardiac rupture/ 
electromechanical disscciation) during the first 30 days. Differences 
between thrombolytic and nonthrombolytic patient groups are evident. 
15% of early deaths. An in-depth analysis of mortality within 
24 h of thrombolysis reported recently by the GUSTO Inves- 
tigators (17) suggested that death within the first 4 h (most 
c&o from pump failure) was not influenced by coronq 
arterial patency, unlike later deaths. These observations have 
important implications. First, they suggest that very early 
deaths may not be preventable even with the early restoration 
of coronary blood flow (at least with current treatment strat- 
egies), possibly as a result of large areas of infarction and a 
profound degree of myocardial stunning (18). Cardiac rupture 
may contribute to these early deaths (17). Second, deaths 
occurring from approximately 6 to 24 h are strongly influenced 
by the establishment of physiologic coronary blood flow, 
suggesting that myocardial ischemia rather than irreversible 
necrosis is operative. Most importantly, there was no evidence 
from the GUSTO angiographic data that the reestablishment 
of coronary arterial blood flow was responsible for “reperfu- 
sion injury’* in the form of either left ventricular dysfunction or 
cardiac rupture. 
Thus, the increased “density” of early deaths with throm- 
bolytic therapy most likely represents a predictable “shift” as 
myocardium is salvaged, preventing later deaths from left 
ventricular dysfunction and an.:mysm formation. As the avail- 
able data do nof support a clinically important contribution 
from either reperfusii myocardial injury or reperfusion ar- 
rhythmias (19), the acceleration of cardiac rupture probably is 
a contributing factor but is not capable of obscuring the clear 
survival advantage offered by thrombolytic therapy. 
Although a majority of patients enrolled in the NRMI 
received thrombolytic therapy within 6 h from symptom onset 
(median 152 min), it is unlikely thai this influenced our ability 
(or inability) to identify an early hazard attributable to delayed 
treatment and rupture (4). A recent analysis of the Late 
As5essment of ThromboIytic E%cacy (LATE) data failed to 
confirm an increased risk of cardiac rupture among patients 
treated with t-PA beyond 12 h from symptom onset. However, 
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by logistic regression, a significant treatment by time to death 
interaction was observed, supporting the hypothesic that 
thrombolysis acceleraies tt.: rusct of cardiac rupture (20). 
Mechanisms of aeceierated rupture in the ffiromboty& 
era. The size, accompanying extent of concomitant ventricular 
dysfunction and location ultimately determine the degree of 
clinical compromise from cardiac rupture. Although surgical 
intervention can be undertaken in selected cases of subacute 
cardiac rupture (21), most acute events are rapidly fatal (7-9). 
In the prethrombolytic era, transmural myocardial r-c&s 
was found to be a pathologic prerequisite for cardiac rupture. 
This may not bc the case in the current era of reperfirsion, 
given the added dimension of myocardial hemorrhage (22-26). 
Conceivably, hemorrhage into an area of nontransmural in- 
farction, if sudden and extensive. could weaken the supporting 
framework of the necrotic zone, predisposing it to sudden 
rupture. Fresh areas of infarction have diminished myocardial 
collagen content (27): this is particularly true at sites of rupture 
(28). Diminution of collagen begins early after infarction and is 
mediated by collagenases (29,30). Plasmin, the active enzyme 
generated by all thrombolytic agents, is capable of digesting 
collagen (31). Although coronary perfusion accelerates neu- 
trophil accumulation in the infarct zone, the absence of a clear 
astiatior; rmong coronary arterial patency. mpcdkl per- 
fusion AX L ardiac rupture suggests that nPu+mphil-mediated 
collagen c+;stion may not play a major role in early events 
(3233). 
A major question that must be explored in the modem 
thrombolytic era is the contribution of fibrinolysii itself and 
concomitant antithrombotic activity to cardiac NptUW Becker 
and van Mantgem (34), in a pathologic analysis of 50 patients, 
described three distinct variants of cardiac rupture after myo- 
cardial infarction. Type 1 rupture was characterized as an 
abrupt, slit-liie myocardial tear correlating clinically with a 
recent infarction (~24 h). In fype II rupture, an area of 
myocardial erosion was evident, indicative of a slowly progres- 
sive tear. Type III rupture correlated with older infa.rtions, 
and the fatal tear typically occurred at a site of aneurysm 
formation. It is conceivable that thrombolytic therapy, through 
the generation of plasmin and the fibrinolytii state coupled 
with systemic anticoagulation and platelet inhibition, acceler- 
ates type I and type II cardiac ~ptures. In contrast, the ability 
of thrombolysi to salvage jeopardized myocardium would be 
expected to reduce ventricular aneurysm formation and thus 
type III cardiac rupture. It is of paramount importance to 
ascertain whether cardiac rupture is, in fact, a hemorrhagic 
complication of thrombolytic therapy (and adjunctire anti- 
th~mbotic treatment). Ongoing dinical trials of increasingly 
poten! thrombdytirs tbmmbin antago&& and platelet inhit&ois 
wiupNvideample~lyloinvesligatethishypotbesis 
Stay Ii&a The NRMI, although the largest of its 
kind, is a simple observational data base. Therefore, compar- 
isons of patient gn#tps should be interpreted with caution. Our 
observations were, however, consistent with those from pK+ 
ously combed dinical trials (16.1720). The diagwsis of 
cardiic rupture was based on clinical rather than strict pati 
13% BECKER ET AL. 
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logic (autopsy) findings. It is possible that the number of events 
was overestimated; however, mitigating against this is the 
likelihood that some cases of rupture may have been miscias- 
sified as sudden cardiac arrest or death from other cardiac 
causes In addition, prior large-scale clinical trials have shown 
that if anything, the incidence of cardiac rupture is underesti- 
mated when clinical diagnostic criteria are used (16,35). Be- 
cause it is not possible to obtain detailed patho!ogic informa 
tion in each case of suspected rupture when tens of thousands 
of patients are being studied, we grouped cardiac rupture 
and electromechanical dissociation. This decision represents 
a precedent set by the ISIS-l Investigators (36) and allows, in 
our opinion, greater chnical applicability of the findings. 
CimcIusIons. In our analysis of over 350,000 patients par- 
ticipating in the NRMI, thrombolytic therapy was associated 
with an increased incidence of eariy deaths attributable to 
card& rupture. The capacity of thrombolysis to accelerate 
cardiac rupture, the apparent “trade OR” between early risk 
and the prevention of later events and the contribution of 
adjunctive therapy (particularly antithrombotic agents) to this 
commonIy fatal event require further investigation. 
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